Cardiovascular disease and vitamin D supplementation: Trial analysis, systematic review, and meta-analysis

American Journal of Clinical Nutrition

Volumn 100, Issue 3, 2014, Pages 746-755

  Ford, John A ^a   MacLennan, Graeme S ^a   Avenell, Alison ^a   Bolland, Mark ^b   Grey, Andrew ^b   Witham, Miles ^c  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; COLECALCIFEROL; PLACEBO; VITAMIN D;

BAYES THEOREM; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; EMBASE; FOLLOW UP; FRACTURE; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HUMAN; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SYSTEMATIC REVIEW; VITAMIN SUPPLEMENTATION; DIET SUPPLEMENTATION; DIET THERAPY; EVIDENCE BASED MEDICINE; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; REPRODUCIBILITY; RISK FACTOR; STROKE; VITAMIN D DEFICIENCY;

DIETARY SUPPLEMENTS; EVIDENCE-BASED MEDICINE; HEART FAILURE; HUMANS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; RISK FACTORS; STROKE; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84907307965     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.113.082602     Document Type: Review

References (50)

1. Beveridge LA, Witham MD. Vitamin D and the cardiovascular system. Osteoporos Int 2013;24:2167-80.
2. Sokol SI, Tsang P, Aggarwal V, Melamed ML, Srinivas VS. Vitamin D status and risk of cardiovascular events: Lessons learned via systematic review and meta-analysis. Cardiol Rev 2011;19:192-201.
3. Reid D, Toole BJ, Knox S, Talwar D, Harten J, O'Reilly DS, Blackwell S, Kinsella J, McMillan DC, Wallace AM. The relation between acute changes in the systemic inflammatory response and plasma 25-hydroxyvitamin D concentrations after elective knee arthroplasty. Am J Clin Nutr 2011;93:1006-11.
4. Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Wetterslev J, Simonetti RG, Bjelakovic M, Gluud C. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev 2014;1:CD007470.
5. Chung M, Balk EM, Brendel M, Ip S, Lau J, Lee J, Lichtenstein A, Patel K, Raman G, Tatsioni A, et al. Vitamin D and calcium: a systematic review of health outcomes. Evid Rep Technol Assess (Full Rep) 2009;183:1-420.
6. Elamin MB, Abu Elnour NO, Elamin KB, Fatourechi MM, Alkatib AA, Almandoz JP, Liu H, Lane MA, Mullan RJ, Hazem A, et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011;96:1931-42.
7. Pittas AG, Chung M, Trikalinos T, Mitri J, Brendel M, Patel K, Lichtenstein AH, Lau J, Balk EM. Systematic review: vitamin D and cardiometabolic outcomes. Ann Intern Med 2010;152:307-14.
8. Wang L, Manson JE, Song Y, Sesso HD. Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med 2010;152:315-23.
9. Witham MD. Vitamin D in chronic heart failure. Curr Heart Fail Rep 2011;8:123-30.
10. Meems LM, van der Harst P, van Gilst WH, de Boer RA. Vitamin D biology in heart failure. Curr Drug Targets 2011;12:29-41.
11. Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, Reid IR. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events. BMJ 2010;341:c3691.
12. Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements with or without vitamin D and risk of cardiovascular events. BMJ 2011;342:f2040.
13. Grant AM, Avenell A, Campbell MK, McDonald AM, MacLennan GS, McPherson GC, Anderson FH, Cooper C, Francis RM, Donaldson C, et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people. Lancet 2005;365:1621-8.
14. Higgins JPT, Altman DG, Sterne JAC. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane handbook. 5.1.0 ed. Chichester, United Kingdom: John Wiley & Sons Ltd, 2011.
15. Stata. Stata statistical software: release 12. College Station, TX: StataCorp, 2011.
16. Gallagher JC, Fowler SE, Detter JR, Sherman SS. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. J Clin Endocrinol Metab 2001;86:3618-28. (Pubitemid 32755952)
17. Gallagher JC, Sai A, Templin T, Smith L. Dose response to vitamin D supplementation in postmenopausal women a randomized trial. Ann Intern Med 2012;156:425-37.
18. Aloia JF, Vaswani A, Yeh JK, Ellis K, Yasumura S, Cohn SH. Calcitriol in the treatment of postmenopausal osteoporosis. Am J Med 1988;84:401-8.
19. Ott SM, Chesnut CH III. Calcitriol treatment is not effective in post-menopausal osteoporosis. Ann Intern Med 1989;110:267-74. (Pubitemid 19062154)
20. Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, Nicholson CG. Annual high-dose oral vitamin D and falls and fractures in older women. JAMA 2010;303:1815-22.
21. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community. BMJ 2003;326:469.
22. Majima T, Komatsu Y, Shimatsu A, Satoh N, Fukao A, Ninomiya K, Matsumura T, Nakao K. Efficacy of combined treatment with raloxifene and alfacalcidol on bone density and biochemical markers of bone turnover in postmenopausal osteoporosis. Endocr J 2008;55:127-34. (Pubitemid 351520189)
23. Attia S, Eickhoff J, Wilding G, McNeel D, Blank J, Ahuja H, Jumonville A, Eastman M, Shevrin D, Glode M, et al. Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. Clin Cancer Res 2008;14:2437-43. (Pubitemid 351551078)
24. DeLuca HF, Bedale W, Binkley N, Gallagher JC, Bolognese M, Peacock M, Aloia J, Clagett-Dame M, Plum L. The vitamin D analogue 2MD increases bone turnover but not BMD in post-menopausal women with osteopenia. J Bone Miner Res 2011;26:538-45.
25. Gorai I, Tanaka Y, Hattori S, Iwaoki Y. Assessment of adherence to treatment of postmenopausal osteoporosis with raloxifene and/or alfacalcidol in postmenopausal japanese women. J Bone Miner Metab 2010;28:176-84.
26. Matsumoto T, Miki T, Hagino H, Sugimoto T, Okamoto S, Hirota T, Tanigawara Y, Hayashi Y, Fukunaga M, Shiraki M, et al. A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation. J Clin Endocrinol Metab 2005;90:5031-6.
27. Xia WB, Zhang ZL, Wang HF, Meng XW, Zhang Y, Zhu GY, Xing XP, Liu JL, Wang LH, Jiang Y, et al. The efficacy and safety of calcitriol and/or caltrate D in elderly chinese women with low bone mass. Acta Pharmacol Sin 2009;30:372-8.
28. Zhu K, Devine A, Dick IM, Wilson SG, Prince RL. Effects of calcium and vitamin D supplementation on hip bone mineral density and calcium-related analytes in elderly ambulatory australian women. J Clin Endocrinol Metab 2008;93:743-9. (Pubitemid 351398548)
29. Lehouck A, Mathieu C, Carremans C, Baeke F, Verhaegen J, van Eldere J, Decallonne B, Bouillon R, Decramer M, Janssens W. High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease. Ann Intern Med 2012;156:105-14.
30. Toss G, Magnusson P. Is a daily supplementation with 40 microgram vitamin D(3) sufficient? Eur J Nutr 2012;51:939-45.
31. Macdonald HM, Wood AD, Aucott LS, Black AJ, Fraser WD, Mavroeidi A, Reid DM, Secombes KR, Simpson WG, Thies F. Hip bone loss is attenuated with 1000 IU but not 400 IU daily vitamin D3. J Bone Miner Res 2013;28:2202-13.
32. Prince RL, Austin N, Devine A, Dick IM, Bruce D, Zhu K. Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women. Arch Intern Med 2008;168:103-8.
33. Witham MD, Price RJ, Struthers AD, Donnan PT, Messow CM, Ford I, McMurdo ME. Cholecalciferol treatment to reduce blood pressure in older patients with isolated systolic hypertension. JAMA Intern Med 2013;173:1672-9.
34. Avenell A, Grant AM, McGee M, McPherson GC, Campbell MK, Group RTM. The effects of an open design on trial participant recruitment, compliance and retention-a randomized controlled trial comparison with a blinded, placebo-controlled design. Clin Trials 2004;1:490-8.
35. McDonagh TA, Morrison CE, Lawrence A, Ford I, Tunstall-Pedoe H, McMurray JJ, Dargie HJ. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 1997;350:829-33. (Pubitemid 27404343)
36. Witham MD, Nadir MA, Struthers AD. Effect of vitamin D on blood pressure. J Hypertens 2009;27:1948-54.
37. Nieminen MS, Harjola VP, Hochadel M, Drexler H, Komajda M, Brutsaert D, Dickstein K, Ponikowski P, Tavazzi L, Follath F, et al. Gender related differences in patients presenting with acute heart failure. Eur J Heart Fail 2008;10:140-8.
38. Shedeed SA. Vitamin D supplementation in infants with chronic congestive heart failure. Pediatr Cardiol 2012;33:713-9.
39. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure. Am J Clin Nutr 2006;83:754-9.
40. Witham MD, Crighton LJ, Gillespie ND, Struthers AD, McMurdo ME. The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure. Circ Heart Fail 2010;3:195-201.
41. Hagström E, Hellman P, Larsson TE, Ingelsson E, Berglund L, Sundstrom J, Melhus H, Held C, Lind L, Michaelsson K, et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 2009;119:2765-71.
42. Schroten NF, Ruifrok WP, Kleijn L, Dokter MM, Sillje HH, Lambers Heerspink HJ, Bakker SJ, Kema IP, van Gilst WH, van Veldhuisen DJ, et al. Short-term vitamin D3 supplementation lowers plasma renin activity in patients with stable chronic heart failure: an open-label, blinded end point, randomized prospective trial (VitD-CHF trial). Am Heart J 2013;166:357-64.
43. Tomaschitz A, Pilz S, Ritz E, Grammer T, Drechsler C, Boehm BO, Marz W. Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system. Clin Chim Acta 2010;411:1354-60.
44. Boxer RS, Kenny AM, Schmotzer MS, Vest M, Fiutem MS, Pina IL. A randomized controlled trial of high-Dose Vitamin D3 in patients with heart failure. JACC Heart Fail 2013;1:84-90.
45. Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, Bassford T, Beresford SAA, Black HR, Blanchette P, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354:669-83. (Pubitemid 43247138)
46. Donneyong MM, Taylor KC, Baumgartner RN, Myers J, Song WL, Martin LW. Calcium plus vitamin D supplementation and the risk of heart failure: the calcium and vitamin D trial of the women's health initiative study. Am J Epidemiol 2013;177:S128.
47. Bolland MJ, Grey A, Gamble GD, Reid IR. The eff ect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. Lancet Diabetes Endocrinol 2014;2:307-20.
48. den Uyl D, Nurmohamed MT, van Tuyl LDH, Raterman HG, Lems WF. (Sub)clinical cardiovascular disease is associated with increased bone loss and fracture risk. Arthritis Res Ther 2011;13:R5.
49. Manson JE, Bassuk SS, Lee IM, Cook NR, Albert MA, Gordon D, Zaharris E, Macfadyen JG, Danielson E, Lin J, et al. The VITamin D and OmegA-3 TriaL (VITAL). Contemp Clin Trials 2012;33:159-71.
50. Pilz S, Rutters F, Dekker JM. Disease prevention: vitamin D trials. Science 2012;338:883.